SHA: 600645

Fuzhou Luyan Pharmacy Secures Exclusive Greater China Rights to French Synergia Brand in Strategic Partnership with Curae LAB
CompanyDeals

Fuzhou Luyan Pharmacy Secures Exclusive Greater China Rights to French Synergia Brand in Strategic Partnership with Curae LAB

Fuzhou Luyan Pharmacy Co., Ltd. ("Luyan Pharma") signed an exclusive strategic cooperation agreement with Curae LAB, a subsidiary of the French GTH Group, for the Synergia brand in Greater China.…

Hangzhou Eli Radiopharma Closes Nearly RMB 400 Million Series A Round – Capital Earmarked for Radiopharmaceutical Pipeline and Radiotheranostic Platform Buildout

Hangzhou Eli Radiopharma Closes Nearly RMB 400 Million Series A Round – Capital Earmarked for Radiopharmaceutical Pipeline and Radiotheranostic Platform Buildout

Amgen's Dazodalibep Hits Phase 3 Milestone in OASIZ‑301 – First Trial to Show Clinically Meaningful Improvement in Systemic Sjögren's Disease Activity

Amgen’s Dazodalibep Hits Phase 3 Milestone in OASIZ‑301 – First Trial to Show Clinically Meaningful Improvement in Systemic Sjögren’s Disease Activity

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Vcanbio Receives NMPA Approval for VUM02 Stem Cell Therapy in Liver Failure and ARDS

CompanyDrug

Vcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis

CompanyDrug

Vcanbio Receives CDE Approval for VUM02 Clinical Trial in Idiopathic Pulmonary Fibrosis

CompanyDrug

Vcanbio’s VUM02 Gains CDE Review for Liver Failure and ARDS Clinical Trials

CompanyDrug

Vcanbio’s Stem Cell Therapy VUM02 Accepted for Clinical Trial Review

CompanyDrug

Vcanbio’s VUM02 Accepted for Review by China’s Center for Drug Evaluation

Show More